We examine Emerging Markets from both the top-down and bottom-up perspectives as we try to identify where to move and what to expect. We check in on two successful EM thematic group ideas as well.
Chinese Pharmaceuticals have been sold off considerably in recent months, but look very attractive on a valuation basis. There are fundamental problems, but in light of China’s objective of universal health care coverage there is significant upside. See “Healthy Tigers” update in “Inside The Stock Market”.